Regeneron Pharmaceuticals And Sanofi Announce That Dupixent® Significantly Reduced COPD Exacerbations In The Second Phase 3 Trial, Accelerating FDA Submission
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals and Sanofi announced positive results from the NOTUS trial for Dupixent, which significantly reduced COPD exacerbations by 34% compared to placebo. The trial confirmed earlier results from the BOREAS trial, and a supplemental BLA submission is planned by the end of 2023. This news could impact the treatment landscape for COPD, as there have been no new treatments approved for over a decade.
November 27, 2023 | 7:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's Dupixent showed a 34% reduction in COPD exacerbations in the NOTUS trial, confirming BOREAS trial results. A supplemental BLA submission is expected by the end of 2023.
The positive trial results for Dupixent in treating COPD are likely to be seen as a significant advancement, potentially leading to increased revenue for Regeneron. The anticipation of a supplemental BLA submission could drive investor optimism in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Sanofi, in partnership with Regeneron, announced successful Phase 3 trial results for Dupixent in COPD treatment, with plans for a supplemental BLA submission by year-end.
Sanofi's collaboration with Regeneron on Dupixent could benefit from the positive trial outcomes, potentially leading to a new revenue stream upon regulatory approval. The market may respond positively to these developments in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90